Data as of Sep 15
| +0.09 / +0.20%|
The 14 analysts offering 12-month price forecasts for Novozymes A/S have a median target of 49.30, with a high estimate of 55.64 and a low estimate of 35.85. The median estimate represents a +9.56% increase from the last price of 45.00.
The current consensus among 14 polled investment analysts is to Hold stock in Novozymes A/S. This rating has held steady since September, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.